

Compound Sales Correction April 16 Reporting (Jan data correction)

As part of an investigation into a query raised by an IMS Health subscriber, we identified that a **single IMS Health supplier** has **underreported compound sales** isolated to **January 2016** reporting. The correct figures have been inserted into April reporting and significant validation has occurred to ensure the issue was limited to January 2016 reporting.

Which IMS Health dataset has been impacted?

Sales have been inserted into Retail, Hospital & Other Outlet Reporting

Did the issue impact multiple month's data?

Additional sales have been inserted into January 2016 reporting only.

Sales are correctly reported for February and March 2016 reporting

Why did the issue occur?

IMS Health receives data from over 100 data suppliers on a regular basis and reports what we receive from these data suppliers. This issue has been limited to 1 data supplier; a result of a transition in systems independent to IMS Health causing an incomplete data feed supplied to IMS Health.

Which markets have been impacted?

Please find below the distribution of sales by ATC Level 3 inserted into April reporting, specifically added to January 2016 reporting:

UNITS

ATC	ATC Description	Jan-16
B03X0	OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID	50,792
L01A0	ALKYLATING AGENTS	1,321,705
L01B0	ANTIMETABOLITES	2,819,657
L01C1	VINCA ALKALOID ANTINEOPLASTICS	788
L01C2	TAXANE ANTINEOPLASTICS	155,919
L01C3	PLANT-BASED ANTINEOPLASTICS	162,969
L01C4	PODOPHYLLOTOXIN ANTINEOPLASTICS	138,386
L01D0	ANTINEOPLASTIC ANTIBIOTICS	2,398,155
L01F0	PLATINUM ANTINEOPLASTICS	28,265
L01G0	MAB ANTINEOPLASTICS	5,000
L01X9	ALL OTHER ANTINEOPLASTICS	167
L04X0	OTHER IMMUNOSUPPRESSANTS	6,850
M05B9	OTHER BONE CALCIUM REGULATORS	3,360
V03D0	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	146,857

VALUES

ATC	ATC Description	Jan-16
B03X0	OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID	\$4,135.32
L01A0	ALKYLATING AGENTS	\$51,807.19
L01B0	ANTIMETABOLITES	\$747,617.41
L01C1	VINCA ALKALOID ANTINEOPLASTICS	\$2,528.93
L01C2	TAXANE ANTINEOPLASTICS	\$717,649.18
L01C3	PLANT-BASED ANTINEOPLASTICS	\$113,195.84
L01C4	PODOPHYLLOTOXIN ANTINEOPLASTICS	\$38,566.12
L01D0	ANTINEOPLASTIC ANTIBIOTICS	\$57,187.31
L01F0	PLATINUM ANTINEOPLASTICS	\$5,277.04
L01G0	MAB ANTINEOPLASTICS	\$19,533.00
L01X9	ALL OTHER ANTINEOPLASTICS	\$98,892.00
L04X0	OTHER IMMUNOSUPPRESSANTS	\$25,177.99
M05B9	OTHER BONE CALCIUM REGULATORS	\$14,753.20
V03D0	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	\$18,448.00

When will the sales be corrected in IMS Health reporting?

The above outlined sales have been included in your April reporting due for despatch this week.

If you have any additional questions, please do not hesitate to ask and we apologise for any inconvenience caused.